The Motley Fool Discussion Boards
Fool Community Help Desk / Ask A Foolish Question
|Subject: Re: clsn||Date: 12/2/2012 6:28 PM|
|Author: culcha||Number: 259759 of 275819|
i think this stock has astronimical upside. anyone else
own it or have any thoughts on it. i think its a no brainer
From the Fool's report, it sounds like it has astronomical upside and astronomical downside as well.
Celsion (NASDAQ: CLSN) traded flat for the first six months of the year, but has picked up considerable momentum this fall now that results from the phase III study of its liver cancer therapy ThermoDox have been confirmed for release in January. Celsion's claim to fame is ThermoDox, a drug based on the company's Lysolipid Thermally Sensitive Liposomes (LTSL) platform being tested in a variety of cancers. The results won't be released until early next year, so consider this the beginning of the speculative fury, with things only intensifying into January.
Make no mistake -- there is significant upside for investors if the liver cancer trial results are good, but the downside is equally massive if ThermoDox were to fail. And those who invest in Celsion while ignoring that risk do so at their own peril. If the phase III study should fail, Celsion will be on the list of worst performing biotech stocks for 2013.
The company has lost money over the last three years. ROE is a high negative number. I'd wait and see how things pan out with them .
|Copyright 1996-2017 trademark and the "Fool" logo is a trademark of The Motley Fool, Inc. Contact Us|